A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma Clinical Trial

Official title:

Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05119335
• Other study ID #: NKT2152-101
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 26, 2021
• Est. completion date: September 2026

Study information

• Verified date: November 2023
• Source: NiKang Therapeutics, Inc.
• Contact: Sponsor Contact
• Phone: (302) 415-5127
• Email: clinicaltrials[@]nikangtx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.

Description:

This is a Phase 1/2 open label multicenter study of NKT2152. Phase 1 is a first in human (FIH) dose escalation study in patients aged 18 years or older with clear cell renal carcinoma (ccRCC) who have exhausted available standard therapy as determined by the investigator. Phase 1 is designed to determine the MTD and/or RDEs of NKT2152 as a single agent administered orally once daily. Depending on the tolerability and PK, additional dosing schedules may be tested. Phase 2 will evaluate the safety, pharmacokinetics and antitumor efficacy of NKT2152 in ccRCC patients. Patients will be randomized to one of two dosage levels selected for further evaluation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 128
• Est. completion date: September 2026
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Patients must meet all of the following criteria to be enrolled in this study.

1. Has the ability to understand and willingness to sign a written informed consent form before the performance of any study procedures

2. Has locally advanced or metastatic ccRCC and has progressed during treatment, are relapsed, refractory and not amenable to curative therapy or standard therapy and has progressed during treatment with at least 1 prior therapeutic regimen

3. Must have measurable disease per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

4. Is of age = 18 years

5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

6. Has a life expectancy of = 3 months

7. Has adequate organ function defined as follows:

1. Bone marrow: ANC = 1.0 × 10^9/L; Hgb level = 10 g/dL without transfusion or erythropoietin support within 2 weeks prior to first dose; platelet count = 75,000/µL

2. Hepatic: transaminase levels (AST/ALT) = 2.5 × ULN (= 5 × ULN if liver metastases is present); total bilirubin (TBILI) = 1.5 × ULN in the absence of Gilbert's disease

3. Renal: serum creatinine level = 2.0 × ULN or calculated creatinine clearance (CrCL) = 40 mL/min (Cockcroft-Gault formula)

8. If a female patient of child-bearing potential, has a negative serum pregnancy test result within 7 days before first study drug administration

9. If a female patient, must be surgically sterile, must be post-menopausal, or must agree to use physician-approved method of birth control during screening, during the study, and for a minimum of 6 months after the last study drug administration; or if a male patient with a female partner, must agree to use physician-approved method of birth control during screening, during the study, and for a minimum of 6 months after the last study drug administration

10. Female patients of childbearing potential must meet all of the following criteria:

1. Not pregnant (negative serum pregnancy test during Screening)

2. Not breast feeding

3. Willing to use a protocol-recommended method of contraception or to abstain from heterosexual intercourse from the start of treatment or until at least 6 months after the last dose of treatment. Note: A female patient is considered to be of childbearing potential unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and follicle-stimulating hormone levels within the institutional laboratory postmenopausal range and a negative serum or urine beta human chorionic gonadotropin); or is menopausal (amenorrhea for 12 months).

11. Male patients who can father a child must meet all of the following criteria:

1. Willing to use a protocol-recommended method of contraception or to abstain from heterosexual intercourse with females of childbearing potential from the start of treatment until at least 6 months after the last dose of treatment, and

2. Willing to refrain from sperm donation from the start of treatment until at least 6 months after the last dose of treatment. Note: A male patient is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.

12. Able to swallow oral medications.

13. Ambulatory subjects need to take a six-minute walk test. Walking distance needs to be at least 400 meters and the change of oxygen saturation needs to be within 5% range. Patients will be excluded from this study if they meet any of the following criteria.

1. Known symptomatic brain metastases requiring > 10 mg/day of prednisone (or its equivalent). Patients with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to the start of NKT2152 treatment, fulfill the above steroid requirement for these metastases, and are neurologically stable based on central nervous system imaging = 4 weeks after CNS-directed treatment.

2. Having one or more of the following conditions:

1. A pulse oximetry reading less than 95% at screening;

2. Any current requirement for intermittent or chronic supplemental oxygen;

3. Any chronic lung condition which has required supplemental oxygen in the past;

4. Evidence of impending airway compromise (such as endobronchial tumor, lymphangitic spread, significant extrinsic compression of major airway) per investigator;

5. Ascites requiring drainage within 28 days prior to W1D1

3. History of another malignancy except for the following: adequately treated local basal cell or squamous carcinoma of the skin, in situ cervical cancer, adequately treated papillary noninvasive bladder cancer, other adequately treated Stage 1 or Stage 2 cancers currently in complete remission, or any other cancer that has been in complete remission for = 2 years

4. Has failed to recover from the effects of prior anticancer therapy to baseline level or Grade 1 severity (except for alopecia) per NCI CTCAE; patients with treatable adverse effects such as hypothyroidism or hypertension may be enrolled if the adverse effect is controlled with treatment

5. Significant cardiovascular disease, including myocardial infarction, arterial thromboembolism, or cerebrovascular thromboembolism, within 6 months prior to start of NKT2152 treatment; symptomatic dysrhythmias or unstable dysrhythmias requiring medical therapy; angina requiring therapy, symptomatic peripheral vascular disease; New York Heart Association Class 3 or 4 congestive heart failure; = Grade 3 hypertension (diastolic blood pressure = 100 mmHg or systolic blood pressure =160 mmHg) despite adequate use of anti-hypertensives; or history of congenital prolonged QT syndrome or repeated demonstration of a QTc interval > 480 ms; ejection fraction < 40%; clinically significant pericardial or pleural effusion in the opinion of the investigator.

6. Has received prior investigational therapy or standard therapy within 5 half-lives of the agent or 4 weeks before the first administration of study drug, whichever is shorter

7. Has a bleeding diathesis or coagulopathy

8. Deep vein thrombosis (DVT)/pulmonary embolism are allowed as long as patient is not symptomatic and received 2 weeks or more of adequate anticoagulation

9. Has manifestations of malabsorption due to prior gastrointestinal (GI) surgery or GI disease

10. Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results

11. Has had major surgery within 4 weeks before first study drug administration; the following procedures are not considered to be major surgeries: thoracentesis, port placement, laparoscopy, thoracoscopy, bronchoscopy, endoscopic or ultrasonographic procedures, mediastinoscopy, skin biopsy, incisional biopsy, image-guided biopsy for diagnostic purposes, and routine dental procedures

12. Has known human immunodeficiency virus (HIV)

13. Has an active infection requiring systemic treatment

14. Is actively participating in another therapeutic clinical trial

Related Conditions & MeSH terms

• Advanced Renal Cell Carcinoma
• Carcinoma
• Carcinoma, Renal Cell
• ccRCC
• Clear Cell Renal Cell Carcinoma
• Hypoxia
• Kidney Cancer
• Kidney Neoplasms
• Metastatic Renal Cell Carcinoma
• Neoplasms
• Recurrent Renal Cell Carcinoma
• Refractory Renal Cell Carcinoma
• Renal Cancer
• Renal Cell Carcinoma
• Renal Neoplasms

Intervention

Drug:
• Oral NKT2152
Oral HIF2a inhibitor

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	National Cancer Institute	Bethesda	Maryland
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Sarah Cannon Research Institute	Denver	Colorado
United States	MD Anderson Cancer Center	Houston	Texas
United States	Indiana University Simon Comprehensive Cancer Center	Indianapolis	Indiana
United States	University of Iowa	Iowa City	Iowa
United States	UCLA	Los Angeles	California
United States	University of Oklahoma	Oklahoma City	Oklahoma
United States	Nebraska Cancer Specialists	Omaha	Nebraska
United States	Oregon Health and Science University	Portland	Oregon
United States	HonorHealth	Scottsdale	Arizona
United States	Seattle Cancer Care Alliance	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
NiKang Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 21 days of dosing) in the Dose Escalation Phase (Phase 1)	DLTs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 .0.	21 days
Primary	Recommended Doses for Expansion (RDEs) Determined in the Dose Escalation Phase (Phase 1)	The RDE(s) will be determined based on observed dose-limiting toxicities (DLTs) and using the totality of (AUC0-8) and biological data in Phase 1.	Approximately 2 years
Primary	Objective Response Rate (ORR) determined by the Investigator in the Dose Expansion Phase (Phase 2)	ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.	Approximately 1 year
Primary	Recommended Phase 2 Dose (RP2D)	Further assess RDEs to determine the RP2D for NKT2152.	Approximately 1 year
Secondary	Number of Participants with Adverse Events	An adverse event (AE) is defined as any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.	Approximately 2 years
Secondary	Area under the plasma concentration time curve (AUC0-t) of NKT2152	Area under the plasma concentration time curve (AUC0-t) of NKT2152.	Up to Day 22
Secondary	Area under the plasma concentration time curve (AUC0-8) of NKT2152	Area under the plasma concentration time curve (AUC0-8) of NKT2152	Up to Day 22
Secondary	Maximum observed plasma concentration (Cmax) of NKT2152	Maximum observed plasma concentration (Cmax) of NKT2152	Up to Day 22
Secondary	Time to maximum observed plasma concentration of NKT2152 (Tmax)	Time to maximum observed plasma concentration of NKT2152 (Tmax)	Up to Day 22
Secondary	Objective Response Rate (ORR) determined by the Investigator in the Dose Escalation Phase (Phase 1)	ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.	Approximately 1 year
Secondary	Duration of response (DOR)	Duration of overall response is defined as the time from the date of first documented CR or PR, assessed by investigator and based on RECIST v. 1.1, to the documented date of progressive disease (PD) or death, whichever occurred first.	Approximately 1 year
Secondary	Disease control rate (DCR) determined by the Investigator	DCR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) or a stable disease (SD) of 8 weeks or longer based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.	Approximately 1 year
Secondary	Progression free survival (PFS)	PFS defined as the time from the date the participant started study drug to the date the participant experiences an event of disease progression or death.	Through study completion, an average of 2 years
Secondary	Overall survival (OS)	OS defined as the time from the date the participant started study drug to death for any reason.	Through study completion, an average of 2 years